Loading company
Odyssey Therapeutics, Inc.
ODTX · Nasdaq · ·
Next earnings: November 4, 2026
$22.48+4.8%Sep 29 close
- 1M
- -7.7%
ODTX · Nasdaq · ·
Next earnings: November 4, 2026
$22.48+4.8%Sep 29 close
Odyssey Therapeutics, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
From the company’s own 8-K filing.
Odyssey Therapeutics, Inc. has no earnings call transcript available.
“Positive clinical proof-of-concept data for OD-001 marked an important milestone for Odyssey and we look forward to sharing additional, supportive data from this trial in October,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Odyssey Therapeutics is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology. Since its founding in 2021, Odyssey has built a portfolio of internally discovered and developed medicines with its first program advancing through multiple clinical milestones. Odyssey’s portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that the Company believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Odyssey Therapeutics, Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.